Carrier system for realizing targeted drug delivery based on glutathione responding to microenvironment active oxygen as well as preparation method and application of carrier system

By using a carrier system based on glutathione response to microenvironmental reactive oxygen species in the preeclampsia, the problems of insufficient targeting and toxicity of drugs in the prior art are solved, and efficient targeted delivery and antioxidant treatment of the placenta are achieved. Improves treatment effect and reduces toxicity to the mother and fetus.

CN118987236AActive Publication Date: 2024-11-22THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Patent Information

Application Number
CN202411096961.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-22
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

The existing targeted drug delivery technology has insufficient drug targeting and potential toxicity problems in preeclampsia treatment, and cannot effectively target the placenta, resulting in poor treatment effect and may cause harm to the mother and fetus.

Method used

Using a carrier system based on glutathione response microenvironmental reactive oxygen species, micelles formed by self-assembly of the two block copolymer PLys-S-PPhe electrostatically adsorbs glutathione and therapeutic genes, and using ROS response to release the drug core. Enhance gene transfection capabilities and achieve antioxidant therapy.

Benefits of technology

The specific release and efficient targeted delivery of drugs in preeclampsia lesions are achieved, reducing toxicity to the maternal and fetus, improving the therapeutic effect and enhancing the stability and efficacy of the carrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987236A_ABST
    Figure CN118987236A_ABST
Patent Text Reader

Abstract

The invention discloses a carrier system for realizing targeted drug delivery based on glutathione responding to microenvironment active oxygen, a preparation method of the carrier system and an application of the carrier system in in-vivo delivery of treatment genes such as FSTL3, an inner core is a micelle formed by self-assembly of a diblock copolymer PLys-S-PPhe, and glutathione and the treatment genes are compounded on the surface of the micelle through an electrostatic adsorption effect. After the carrier system enters a focus, GSH adsorbed by a shell reacts with ROS of the focus, a microenvironment anti-oxidation treatment effect is generated, after obvious shell dissociation, strong positive electricity core 'PLys-S-PPhe' release, core release and overall surface positive electricity increase of the medicine occur, endocytosis of lesion cells in the placenta is easily promoted, and a cell targeting delivery effect of FSTL3 and other medicines is generated; according to the present invention, with the application of the compound, the focus targeting retention effect of the positive electric core is generated, the efficient distribution similar to the focus targeting in the placenta is achieved, the toxicity to the maternal body or the fetus is reduced, and the new carrier is provided for the drug for treating the diseases related to the oxidative stress in the placenta.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and nanomedicine, and specifically relates to a carrier system for realizing targeted drug delivery based on glutathione response to active oxygen in microenvironment, and a preparation method and application thereof. Background Art

[0002] Preeclampsia is a placental disease that seriously endangers the health of mothers and infants, and there is a lack of therapeutic targets in clinical practice. The etiology and pathogenesis of preeclampsia have always been an important research topic in obstetrics. Over the years, it has been found that there are many pathological changes in the development of preeclampsia, such as impaired endothelial cell function, insufficient spiral artery remodeling, inflammatory activation, inability to maintain immune tolerance, and even genetic factors. Although there is still no effective theory of the pathogenesis of preeclampsia, it can comprehensively guide the diagnosis and treatment of PE to improve the efficacy of preeclampsia.

[0003] At present, the antihypertensive drugs and antispasmodics recommended in the first-line clinical guidelines only have the effect of relieving symptoms and have failed to show the effect of improving the prognosis of preeclampsia in clinical trials [Annu Rev Pathol. 2010; 5: 173-92.]. However, the problem of targeted drug delivery to the placenta has not been solved, and a large number of drugs are listed as prohibited or used with caution due to potential maternal and fetal toxicity. Therefore, even if the therapeutic targets in the placenta are extracted, the previous technology cannot be effective in vivo. Because drugs that cannot be targeted for placental distribution have potential maternal / fetal toxicity, they cannot be used [Clin Sci. 2021Sep 17; 135(17): 2049-2066.].

[0004] Existing targeted delivery drugs such as PEI have obvious biological toxicity, or are difficult to excrete and degrade, and cannot be used for placental and maternal and fetal diseases. Biological carriers (amino acids, cholesterol, bile acid) have high biological safety, are easily degraded after being absorbed by cells, and have high bioavailability [Pharmacol Ther. 2022Feb; 230: 107964.]. However, they are easily degraded during the distribution process, have poor stability, and have low drug loading efficiency [Hum Reprod Update. 2015Jan-Feb; 21(1): 97-118.].

[0005] Polylysine nanocarriers are also widely studied as gene delivery carriers in clinical practice because they have a high positive charge, can be completely degraded in the body, have a controllable structure and good monodispersity. However, compared with classic high-positive materials such as PEI, their gene loading efficiency is low. In order to improve the gene loading efficiency, high-generation dendritic polylysine nanoparticles inevitably have increased positive charge and enhanced cytotoxicity [Adv Drug Deliv Rev. 2020; 160: 199-211.]. Appropriate structural design and modification methods are needed to reduce the charge and toxicity of polylysine. In addition, the lack of targeting of the distribution of lysine carriers in the body may reduce the efficacy of drugs in the placenta and increase the potential toxicity of drugs outside the placenta. Therefore, it is necessary to improve its targeting of lesion distribution. Summary of the invention

[0006] In order to overcome the deficiencies and shortcomings of the prior art, the purpose of the present invention is to provide a carrier system for targeted drug delivery based on glutathione response to microenvironmental reactive oxygen species, and its preparation method and application. The present invention uses GSH as an outer shell to shield the strong positive charge of the inner core of the amino acid gene carrier. After reacting with ROS in the lesion, the outer shell falls off, and the positive charge of the inner core of the drug is exposed, thereby enhancing the gene transfection ability of the diseased cells, and the diseased cells obtain the loaded FSTL3 and other genes for treatment. This therapeutic effect has a mutually reinforcing beneficial effect with the antioxidant therapeutic effect of ROS loaded by the drug shell.

[0007] The purpose of the present invention is achieved through the following technical solutions:

[0008] A carrier system for achieving targeted drug delivery based on glutathione responding to active oxygen in the microenvironment. The core of the carrier system is a micelle formed by self-assembly of a diblock copolymer PLys-S-PPhe, and glutathione and therapeutic genes are compounded on the surface of the micelle through electrostatic adsorption.

[0009] It is currently found that oxidative stress and increased ROS in the placenta caused by ischemia and hypoxia are basic metabolic manifestations in the placenta. The level of ROS in the placental microenvironment of preeclampsia is much higher than that in normal tissues. Excessive production of ROS can be regarded as a recognition target for targeted drug delivery. Designing and synthesizing ROS-responsive carrier materials by introducing groups with ROS response is an effective method for achieving targeted drug delivery in the placenta of preeclampsia. Glutathione (glutathione, r-glutamyl cysteingl+glycine, GSH) is a tripeptide containing γ-amide bonds and sulfhydryl groups, composed of glutamic acid, cysteine ​​and glycine, present in almost every cell of the body, with antioxidant and detoxification effects. The present invention achieves specific release of drugs in preeclampsia lesions by introducing glutathione (glutathione, r-glutamyl cysteingl+glycine, GSH) that responds to ROS in the placental microenvironment in the carrier. The GSH that disintegrates in the lesion reacts with ROS and plays a role in microenvironment antioxidant therapy. This antioxidant effect in the microenvironment can enhance the therapeutic effect of the gene loaded by the nanocarrier. At the same time, the reaction of the GSH shell leads to the release of the positively charged carrier loaded with the gene, producing an effect similar to lesion-targeted delivery.

[0010] The structural formula of the diblock copolymer PLys-S-PPhe of the present invention is:

[0011]

[0012] Among them, x=40-60, y=20-30.

[0013] Preferably, the therapeutic gene is FSTL3. Follistatin-like 3 (FSTL3) gene, also known as FLRG (Follistatin related-gene), is a binding protein of TGF-β superfamily members. It can specifically bind to multiple members of TGF-β superfamily such as myostatin, activin, bone morphogenetic protein (BMPs), GDF-11, etc., inhibit Smad-mediated intracellular signal transduction, and then inhibit the biological functions of TGF-β superfamily members. Follistatin-like3 is significantly highly expressed in placenta, mature testis, heart and pancreatic tissues. The human FSTL3 gene is located in the human chromosome 19p13 region. The FSTL3 gene consists of 5 exons and 4 introns, encoding a signal peptide, an N-terminal domain, two FS regions and a C-terminal domain. Overexpression of FSTL3 may activate epithelial-mesenchymal transition (EMT) by promoting F-actin expression and BMP / SMAD signaling. FSTL3 binds to activinA in the placenta, reducing the ability of activinA to bind to its receptor, thereby regulating cell growth, differentiation, and immune response through the regulation of TGF-β pathway activity. FSTL3 has been found to be a key factor in the onset of preeclampsia and can be used as a therapeutic target for preeclampsia. The present invention combines it with the surface of the inner core through electrostatic adsorption to achieve an effective therapeutic effect on preeclampsia.

[0014] Preferably, the surface potential of the diblock copolymer PLys-S-PPhe is 20 to 42 mV.

[0015] Preferably, the surface potential of the carrier system is 3-15 mV.

[0016] The present invention also provides a method for preparing the above-mentioned carrier system for realizing targeted drug delivery based on glutathione responding to microenvironment active oxygen, comprising the following steps:

[0017] (1) Using n-butylamine as an initiator, the ring-opening polymerization of N6-benzyloxycarbonyl-L-lysine cyclic anhydride Lys-NCA was initiated to obtain poly (N-benzyloxycarbonyllysine) PZLL;

[0018] (2) PZLL and acrylic acid are connected by amidation reaction to introduce double bonds, thereby synthesizing double-bond terminated poly(N-benzyloxycarbonyllysine)-vinyl PZLL-vinly;

[0019] (3) PZLL-vinly was treated with azobisisobutyronitrile to add double bonds with the thiol group of cysteamine to synthesize the amino-terminated polymer PZLL-S-NH2 connected by thioether bonds;

[0020] (4) Using the terminal amino group of PZLL-S-NH2 as an initiator, the ring-opening polymerization of L-phenylalanine-N-carboxyl ring anhydride Phe-NCA was initiated to obtain PZLL-S-PPhe;

[0021] (5) after the benzyl ester group of the PZLL-S-PPhe side chain is removed by deprotection, the PZLL-S-PPhe is self-assembled in an aqueous solution to form polylysine-thioether bond-polyphenylalanine PLys-S-PPhe nanoparticles;

[0022] (6) PLys-S-PPhe nanoparticles were prepared with glutathione and therapeutic genes through electrostatic adsorption to form a carrier system based on glutathione response to microenvironmental reactive oxygen species for targeted drug delivery.

[0023] Preferably, in step (2), the molar ratio of PZLL to acrylic acid is 1:1 to 1:2.

[0024] Preferably, in step (3), the molar ratio of PZLL-vinly to cysteamine is 1:1 to 1:2.

[0025] On the other hand, the present invention also provides the use of the above-mentioned glutathione-based carrier system for achieving targeted drug delivery in response to microenvironmental reactive oxygen species in the preparation of drugs for treating diseases related to intraplacental oxidative stress.

[0026] Preferably, the intraplacental oxidative stress-related disease is preeclampsia.

[0027] Compared with the prior art, the present invention has the following excellent effects:

[0028] The synthesized diblock copolymer PLys-S-PPhe of the present invention has amphiphilicity, self-assembles in aqueous solution to form nano micelles, and due to the high positive charge property of its own chain polylysine, glutathione and therapeutic genes can be compounded on the surface of micelles through electrostatic adsorption. After entering the lesion, the GSH adsorbed by the shell reacts with the lesion ROS, and plays an extracellular antioxidant therapeutic effect in the placental microenvironment. After the antioxidant reaction occurs, the GSH shell dissociates, and the strong positive charge of the inner core of the drug-containing PLys-S-PPhe carrier is exposed. After the overall positive charge of the nanocarrier surface increases, it is easy to promote the endocytosis of the diseased cells in the placenta. After the endocytosis, the "thioether bond" of the drug inner core dissociates in the cell in a targeted manner, further promoting the disintegration of the inner core and the release of the drug, producing a cell-targeted delivery effect of the drug, and also producing a lesion-targeted retention effect of the positively charged inner core, realizing efficient distribution similar to lesion targeting in the placenta, with low liver and kidney toxicity, reducing the toxicity to the mother or fetus, and providing a new carrier for drugs for treating oxidative stress-related diseases in the placenta. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 The synthetic route for the PLys-S-PPhe core is shown;

[0030] Figure 2 A schematic diagram of the structure of a carrier system for achieving targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen prepared in an embodiment of the present invention;

[0031] Figure 3 This is an electron micrograph of a carrier system for achieving targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen species prepared in an embodiment of the present invention. DETAILED DESCRIPTION

[0032] The present invention is further described below by means of specific implementation methods. The following examples are specific implementation methods of the present invention, but the implementation methods of the present invention are not limited to the following examples.

[0033] The sources of the raw materials used in the embodiments of the present invention are shown in Table 1 below:

[0034] Table 1

[0035]

[0036]

[0037] Example 1: Preparation of a carrier system for targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen species

[0038] (1) Synthesis of poly(N-benzyloxycarbonyllysine) (PZLL)

[0039] With n-butylamine as initiator, N6-benzyloxycarbonyl-L-lysine cyclic anhydride (Lys-NCA) was initiated to initiate the ring-opening polymerization to obtain PZLL. The specific operation of synthesizing PZLL is as follows: weigh Lys-NCA (1.53g, 5mmol, 50eq.), put it into a Shrek bottle completely dried in an oven, ventilate it with nitrogen three times, seal it and add 20mL DMF with a syringe, stir and dissolve it at 35℃, then add 5mL of DMF solution of n-butylamine (7.3mg, 0.1mmol, 1.0eq.) prepared, seal it in a nitrogen environment to isolate the air, and stir and react in an oil bath at 35℃ for 72h. After the reaction is completed, the reactant is precipitated with excess ether to obtain transparent and viscous PZLL, which is redissolved in chloroform and precipitated with excess ether to obtain a white solid. Dry it in vacuum at 40℃ for 24 hours to obtain pure PZLL powder with terminal amino group, which is stored at 4℃ for later use.

[0040] (2) Synthesis of double-bond terminated poly(N-benzyloxycarbonyllysine) (PZLL-vinly)

[0041] PZLL and acrylic acid were connected by amidation reaction to introduce double bonds, and double-bond terminated poly(N-benzyloxycarbonyllysine)-vinyl (PZLL-vinly) was synthesized. The specific synthesis operation is as follows: under nitrogen protection, 1.3g PZLL (6500g / mol, 0.2mmol, 1.0eq.), 46.6mg EDC (155.25g / mol, 0.3mmol, 1.5eq.) and 37mg NHS (115.09g / mol, 0.3mmol, 1.5eq.) were added to a 100mL reaction bottle, and 50mL of freshly distilled chloroform was added to dissolve, and the reaction was stirred at room temperature for 1h. 14.4 mg of acrylic acid (72 g / mol, 0.2 mmol, 1.0 eq.) was added, and the mixture was reacted at room temperature for 24 h. After filtering out the insoluble DCU, the mixture was precipitated in a large amount of cold anhydrous ether, filtered, washed with anhydrous ethanol, ultrapure water with pH 5.0, anhydrous ethanol, and anhydrous ether in sequence, and dried to obtain the product PZLL-vinly;

[0042] (3) Synthesis of amino-terminated poly(N-benzyloxycarbonyllysine) (PZLL-S-NH2) with thioether bonds

[0043] Under the initiation of azobisisobutyronitrile (AIBN), the thiol group of cysteamine was added to the double bond to synthesize the amino-terminated polymer PZLL-S-NH2 connected by a thioether bond. The specific synthesis operation is as follows: In a 50mL reaction bottle, 655mg PZLL-vinly (6550g / mol, 0.10mmol, 1.0eq.), 154mg cysteamine (77.15g / mol, 2mmol, 20eq.) and 2.5mg AIBN (164.21g / mol, 0.015mmol, 0.15eq.) synthesized above were dissolved in 20mL anhydrous DMSO, heated and stirred at 70°C for 48h, the reaction solution was dialyzed in anoxic water in a dialysis bag with a molecular cutoff of 3.4kDa for two days, and freeze-dried to obtain PZLL-S-NH2;

[0044] (4) Synthesis of poly(N-benzyloxycarbonyllysine)-polyphenylalanine (PZLL-S-PPhe) linked by thioether bonds

[0045] The terminal amino group of PZLL-S-NH2 is used as an initiator to initiate the ring-opening polymerization of L-phenylalanine-N-carboxyl ring anhydride (Phe-NCA) to obtain PZLL-S-PPhe. The specific operation of synthesizing PZLL is as follows: The above-synthesized PZLL-S-NH2 (6600g / mol, 0.66g, 0.1mmol, 1.0eq.) product and Phe-NCA (0.573g, 3mmol, 30eq.) are added to a Shrek bottle completely dried in an oven, ventilated with nitrogen three times, sealed and added with a syringe 25mL DMF (2wt%), stirred in a 35℃ oil bath for 24h, after the reaction is completed, the reactant is precipitated with excess ether to obtain PZLL-S-PPhe white solid. Pure terminal amino PZLL-S-PPhe powder is obtained by vacuum drying at 40℃ for 24h, and stored at 4℃ for later use.

[0046] (5) Deprotection of PZLL-S-PPhe

[0047] The prepared PZLL-S-PPhe (2.0 g) was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced, and the reaction was bubbling for 30 min, and the reaction was continued for 12 h in an ice bath, and then precipitated with excess ether to obtain the deprotected product. The deprotected polylysine-thioether bond-polyphenylalanine (PLys-S-PPhe) was obtained by vacuum drying at 40°C for 24 h.

[0048] (6) Preparation of PLys-S-PPhe Nanoparticles

[0049] The prepared PLys-S-PPhe can be self-assembled in aqueous solution to form nanoparticles. The specific operation is as follows: 20 mg of PLys-S-PPhe is completely dissolved in 5 mL of PBS aqueous solution, and then the nanoparticles are dispersed under ultrasound. After the ultrasound, the solution is filtered with a water filter (pore size: 0.45 μm) to remove large aggregates, and then dialyzed in PBS (pH 7.4) with a dialysis bag (molecular cutoff: 14 kDa) for 2 days to remove polymers that have not formed particles, and obtain a PLys-S-PPhe nanoparticle solution. Figure 1 The synthetic route of PLys-S-PPhe nanoparticles is shown.

[0050] (7) Preparation of FSTL3 plasmid-complexed PLys-S-PPhe nanoparticles

[0051] The FSTL3 plasmid composite nano-PLys-S-PPhe carrier was prepared by electrostatic adsorption. The specific operation was as follows: 500 μg of FSTL3 plasmid was diluted with PBS to a final volume of 1.5 mL, and then the diluted FSTL3 plasmid solution was mixed with the nano-polylysine particle solution, and after being blown and mixed and allowed to stand for 30 minutes, the solution was placed in a dialysis bag (molecular cutoff: 14 kDa), and dialyzed for 24 hours to remove unreacted plasmids, and uniform FSTL3 plasmid composite PLys-S-PPhe nanoparticles were obtained.

[0052] (8) Preparation of a carrier system based on glutathione to achieve targeted drug delivery in response to microenvironmental reactive oxygen species

[0053] The positively charged FSTL3 plasmid-complexed PLys-S-PPhe nanoparticles and the negatively charged glutathione GSH can be combined to form a nanocomplex through electrostatic interaction. The specific operation is as follows: the prepared GSH aqueous solution (0.2g / mL, 10mL) is added dropwise into the FSTL3 plasmid-complexed PLys-S-PPhe nanoparticle solution (200mg / mL, 5mL) at a rate of 0.5mL / min and stirred for 1h. Finally, the solution is placed in a dialysis bag (molecular cutoff: 14kDa) and dialyzed for 24h to remove unreacted GSH, then concentrated with an ultrafiltration tube (molecular cutoff: 100kDa), and finally washed with PBS (pH 7.4) and filtered through an aqueous filter head (pore size: 0.22μm) to obtain a carrier system (GSH@PLys-S-PPhe) based on glutathione response to microenvironment reactive oxygen species to achieve targeted drug delivery.

[0054] Figure 2The schematic diagram of the structure of the prepared carrier system is shown. It can be seen from the figure that the core of the carrier system is a micelle formed by self-assembly of the diblock copolymer PLys-S-PPhe, and glutathione and therapeutic genes are complexed on the surface of the micelle through electrostatic adsorption.

[0055] Figure 3 An electron micrograph of the prepared carrier system is shown.

[0056] Comparative Example 1: Synthesis of PEG-PLys-S-PPhe and preparation of nanocarriers loaded with therapeutic gene plasmids

[0057] (1) Synthesis of polyethylene glycol-poly (N-benzyloxycarbonyl lysine) (mPEG-PZLL)

[0058] mPEG-PZLL was synthesized by ring-opening polymerization. mPEG-NH2 was used as an initiator to initiate the ring-opening polymerization of N6-benzyloxycarbonyllysine-L-carbonyl anhydride (Lys-NCA) to obtain mPEG-PZLL. The specific operation of synthesizing mPEG-PZLL is as follows: 1.53g of Lys-NCA (5mmol) was weighed and placed in a Shrek bottle completely dried in an oven, ventilated three times with nitrogen, sealed and added with a syringe 20mL DMF, stirred and dissolved at 35℃, and then 5mL of mPEG-NH2 (0.23g, 0.1mmol) DMF solution prepared above was added, sealed and isolated from air under nitrogen environment, and stirred in an oil bath at 35℃ for 72h. After the reaction was completed, the reactant was precipitated with excess ether to obtain transparent and viscous mPEG-PZLL, which was redissolved in chloroform and precipitated with excess ether to obtain a white solid. Pure amino-terminated mPEG-PZLL powder was obtained by vacuum drying at 40°C for 24 h;

[0059] (2) Synthesis of double bond-terminated polyethylene glycol-poly(N-benzyloxycarbonyllysine) (mPEG-PZLL-vinly)

[0060] mPEG-PZLL and acrylic acid were connected by amidation reaction to introduce double bonds to synthesize double-bond-terminated polyethylene glycol-poly(N-benzyloxycarbonyllysine)-vinyl (mPEG-PZLL-vinly). The specific synthesis operation is as follows: Under nitrogen protection, 1.7g mPEG-PZLL (8500g / mol, 0.2mmol, 1.0eq.), 46.6mg EDC (155.25g / mol, 0.3mmol, 1.5eq.) and 37mg NHS (115.09g / mol, 0.3mmol, 1.5eq.) were added to a 100mL reaction bottle, and 50mL of freshly distilled chloroform was added to dissolve, and the reaction was stirred at room temperature for 1h. 14.4 mg of acrylic acid (72 g / mol, 0.2 mmol, 1.0 eq.) was added, and the mixture was reacted at room temperature for 24 h. After the insoluble DCU was removed by filtration, the mixture was precipitated in a large amount of cold anhydrous ether, filtered, washed with anhydrous ethanol, ultrapure water at pH 5.0, anhydrous ethanol and anhydrous ether in sequence, and dried to obtain the product mPEG-PZLL-vinly;

[0061] (3) Synthesis of amino-terminated polyethylene glycol-poly(N-benzyloxycarbonyllysine) (mPEG-PZLL-S-NH2) with thioether bonds

[0062] Under the initiation of azobisisobutyronitrile (AIBN), the thiol group of cysteamine was added to the double bond to synthesize the amino-terminated polymer mPEG-PZLL-S-NH2 connected by a thioether bond. The specific synthesis operation is as follows: In a 50mL reaction bottle, 855mg of the above-synthesized mPEG-PZLL-vinly (8550g / mol, 0.10mmol, 1.0eq.), 154mg of cysteamine (77.15g / mol, 2mmol, 20eq.) and 2.5mg of AIBN (164.21g / mol, 0.015mmol, 0.15eq.) were dissolved in 20mL of anhydrous DMSO, heated and stirred at 70°C for 48h, and the reaction solution was dialyzed in anoxic water in a dialysis bag with a molecular cutoff of 3.4kDa for two days, and freeze-dried to obtain mPEG-PZLL-S-NH2;

[0063] (4) Synthesis of polyethylene glycol-poly(N-benzyloxycarbonyllysine)-polyphenylalanine (mPEG-PZLL-S-PPhe) linked by thioether bonds

[0064] The terminal amino group of mPEG-PZLL-S-NH2 was used as an initiator to initiate the ring-opening polymerization of L-phenylalanine-N-carboxyl cyclic anhydride (Phe-NCA) to obtain mPEG-PZLL-S-PPhe. The specific operation of synthesizing mPEG-PZLL-S-PPhe is as follows: The above-synthesized mPEG-PZLL-S-NH2 (8600g / mol, 0.86g, 0.1mmol, 1.0eq.) product and Phe-NCA (0.573g, 3mmol, 30eq.) were added to a Shrek bottle completely dried in an oven, ventilated with nitrogen three times, sealed and added with a syringe 25mL DMF (2wt%), stirred in a 35℃ oil bath for 24h, and after the reaction was completed, the reactant was precipitated with excess ether to obtain a white solid. Pure mPEG-PZLL-S-PPhe powder was obtained by vacuum drying at 40℃ for 24h and stored at 4℃ for later use;

[0065] (5) Deprotection of mPEG-PZLL-S-PPhe

[0066] The mPEG-PZLL-S-PPhe (1.2 g) prepared above was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced, and the reaction was bubbled for 30 min, and the reaction was continued for 12 h in an ice bath, and then precipitated with excess ether to obtain the deprotected product. The deprotected polyethylene glycol-polylysine-thioether bond-polyphenylalanine (mPEG-PLys-S-PPhe) was obtained by vacuum drying at 40°C for 24 h;

[0067] (6) Preparation of mPEG-PLys-S-PPhe gene composite nanocarrier

[0068] Positively charged mPEG-PLys-S-PPhe nanoparticles and negatively charged FSTL3 plasmids can form nanocomplexes through electrostatic interaction. The specific operation is as follows: 500 μg of FSTL3 plasmid was diluted with PBS to a final volume of 1.5 mL and oscillated evenly. 25 mg of mPEG-PLys-S-PPhe was dissolved in 5 mL of PBS solution, and then the diluted solution of FSTL3 plasmid was added dropwise to the PBS solution (pH 7.4) of the nanocarrier at a rate of 0.5 mL / min under ultrasound. After the ultrasound was finished, the mixture was blown and allowed to stand for 30 minutes, and filtered with an aqueous filter head (pore size: 0.45 μm) to remove large aggregates. Subsequently, the solution was placed in a dialysis bag (molecular cutoff: 14 kDa) and dialyzed for 24 h to remove unreacted plasmids. After washing with PBS (pH 7.4), it was filtered through an aqueous filter (pore size: 0.22 μm) to obtain uniform FSTL3 plasmid-complexed mPEG-PLys-S-PPhe nanocarriers.

[0069] Comparative Example 2: Synthesis of polylysine-polyphenylalanine (PLys-PPhe) and preparation of nanocarriers loaded with therapeutic gene plasmids

[0070] (1) Using the amino-terminated PZLL synthesized in S1 as an initiator, the ring-opening polymerization of phenylalanine N-carbonylcarboxylic anhydride (Phe-NCA) was initiated to obtain poly(N-benzyloxycarbonyllysine)-polyphenylalanine (PZLL-PPhe). The specific operation is as follows: weigh 1.5g of the PZLL product synthesized above, add the amino-terminated PZLL and Phe-NCA (0.573g, 3mmol) into a Shrek bottle completely dried in an oven, ventilate with nitrogen three times, seal it, add 25mL DMF (2wt%) with a syringe, and stir in an oil bath at 35℃ for 24h. After the reaction is completed, the reactant is precipitated with excess ether to obtain a transparent viscous polymer product, and the viscous substance is redissolved in chloroform and precipitated with excess ether to obtain a white solid PZLL-PPhe.

[0071] (2) After obtaining PZLL-PPhe, a deprotection operation was performed: the PZLL-PPhe prepared above (1.0 g) was dissolved in trifluoroacetic acid (0.04 g / mL), and then hydrogen bromide gas was introduced, and the bubbling reaction was carried out for 30 minutes. The reaction was continued in an ice bath with stirring for 12 hours, and then precipitated with excess ether to obtain a deprotected product. The deprotected polylysine-polyphenylalanine (PLys-PPhe) was obtained by vacuum drying at 40°C for 24 hours.

[0072] (3) Positively charged PLys-PPhe nanoparticles and negatively charged FSTL3 plasmids can form nanocomplexes through electrostatic interaction. The specific operation is as follows: 500 μg of FSTL3 plasmid was diluted with PBS to a final volume of 1.5 mL and shaken evenly. 20 mg of PLys-PPhe was dissolved in 5 mL of PBS solution, and then the diluted solution of FSTL3 plasmid was added dropwise to the PBS solution (pH 7.4) of the nanocarrier at a rate of 0.5 mL / min under ultrasound. After the ultrasound was completed, the solution was blown and allowed to stand for 30 minutes, and filtered with an aqueous filter head (pore size: 0.45 μm) to remove large aggregates. Subsequently, the solution was placed in a dialysis bag (molecular cutoff: 14 kDa), dialyzed for 24 hours to remove unreacted plasmids, washed with PBS (pH 7.4), and filtered through an aqueous filter head (pore size: 0.22 μm) to obtain uniform FSTL3 plasmid-complexed PLys-PPhe nanocarriers.

[0073] (4) The positively charged FSTL3 plasmid-PLys-PPhe nanoparticles and the negatively charged GSH can form a nanocomplex through electrostatic interaction. The specific operation is as follows: the prepared GSH aqueous solution (0.2g / mL, 10mL) is added dropwise into the PLys-PPhe nanoparticle solution (200mg / mL, 5mL) at a rate of 0.5mL / min and stirred for 1h. Finally, the solution is placed in a dialysis bag (molecular cutoff: 14kDa) and dialyzed for 24h to remove unreacted GSH. The GSH@PLys-PPhe nanoparticle solution is then concentrated using an ultrafiltration tube (molecular cutoff: 100kDa), and finally washed with PBS (pH 7.4) and filtered through an aqueous filter head (pore size: 0.22μm) to obtain the GSH@PLys-PPhe nanocarrier.

[0074] Examples 2-3 and Comparative Examples 3-5:

[0075] As shown in Table 2, the amount of Lys-NCA in step (1), the amount of Phe-NCA in step (4) and the amount of GSH in step (4) were changed, and the rest was the same as in Example 1.

[0076] Table 2: Examples and Comparative Examples

[0077]

[0078] The carrier systems prepared in the examples and comparative examples were subjected to functional evaluation experiments as follows:

[0079] 1. Near-infrared in vivo fluorescence (NIRF) molecular imaging experiments to evaluate the placenta-specific delivery function of drugs

[0080] Model building:

[0081] 8-week-old SPF-grade C57BL / 6 mice (purchased from Guangdong Medical Experimental Animal Center) were mated with male mice in a 2:1 ratio during estrus. The vaginal secretion smears of female mice were stained with Papanicolaou on the second day. The specimens with positive vaginal sperm were observed under an optical microscope and diagnosed as pregnancy, which was marked as pregnancy day 0 (D0). Pregnant mice were fed with 2 mg / mL nitroso-L-arginine methyl ester dissolved in sterile water to establish the preeclampsia / gestational hypertension model, and pregnant mice fed with an equal amount of double distilled water served as the normal control group.

[0082] NIRF imaging detects the placental distribution of drugs:

[0083] The near-infrared dye CY7 was used for vector staining and tracing. On the 11th day, the preeclampsia model animals were anesthetized with chloral hydrate, and the distribution of drugs containing near-infrared fluorescent dyes in vivo was observed before drug injection (0h) and 2 hours after injection (2h). The dose of nm drug injected into the tail vein was: (therapeutic dose 12.5μg nucleic acid equivalent drug, or an equal volume of PBS); C57BL / 6j mice were imaged in vivo using the In vivo FX in vivo fluorescence scanner. The relative increase ratio of the signal in the placenta region (uterine region in the lower abdomen of the mouse) or the liver region at 2h after drug injection (RSI (Relative Signal Intensity) % = R2h / R0h) was calculated, and the results are shown in Table 3.

[0084] Table 3 Placenta-specific delivery function evaluation results

[0085] Group Placenta RSI (signal relative multiple) Liver RSI (relative signal multiple) Example 1 1.0 1.0 Example 2 0.9 1.3 Example 3 1.1 0.9 Comparative Example 1 0.8 1.0 Comparative Example 2 1.0 1.0 Comparative Example 3 1.1 0.9 Comparative Example 4 0.7 1.5 Comparative Example 5 0.6 1.5

[0086] 2. Establishing an animal model of preeclampsia to evaluate the therapeutic effect

[0087] 12.5 μg nucleic acid equivalent drug or an equal volume of normal saline was injected on D3, D6, D9, D12, and D15, and a series of tests were performed on D17. The test results are shown in Table 4:

[0088] Blood pressure test: Use the BP-2000 blood pressure analysis system to non-invasively measure the systolic blood pressure (SBP) of pregnant mice using the tail cuff method. Maintain the room temperature at 26 degrees Celsius, set channel 1 to 1V (1V is equivalent to 300mmHg), and channel 2 to SmV. Fix the mouse in a cage, place the mouse's tail in a 17mm tail cuff, and make sure the bottom of the tail contacts the sensor. When the pregnant mouse is in a quiet state, continuously apply pressure and measure 10 times, with an interval of 1s each time, take the average value and keep a record;

[0089] Placenta and fetus examination: Placenta tissue: Pregnant mice were killed, the abdominal cavity was opened, the uterus was dissected, and the fetuses and placenta were taken out in turn, and the number of surviving fetuses was recorded. The fetal membrane and umbilical cord on the placenta were removed, and the umbilical cord at the fetal end was cut off along the root of the umbilical cord. The placenta and fetus were placed on sterile gauze to absorb the surface amniotic fluid, and the fetus was weighed on an analytical balance. The cut placenta tissue was placed in liquid nitrogen and stored at -80℃.

[0090] Table 4 Evaluation of therapeutic effects in animal models of preeclampsia

[0091] Group Blood pressure (mmHg) Fetal weight (g) Number of piglets per litter Disease-free, PBS injection control 103.5 1.7 8.0 Example 1 109.2 1.5 7.5 Example 2 112.3 1.4 7.0 Example 3 113.6 1.3 7.1 Comparative Example 0, Disease Group PBS 161.3 0.9 3.5 Comparative Example 1 131.0 1.2 6.2 Comparative Example 2 138.5 1.2 6.0 Comparative Example 3 139.3 1.3 6.2 Comparative Example 4 145.2 1.1 5.7 Comparative Example 5 152.3 1.0 5.5

[0092] As shown in Tables 3 and 4, the strong positive potential (+20-42mV) of the core of the PLys-S-PPhe carrier in Examples 1-3 is shielded by the adsorbed GSH shell as a weaker positive potential, which prevents strong positive electrical stimulation of the liver-based reticuloendothelial system from being engulfed in the blood circulation process before entering the lesion. The overall potential of these drugs is within (+3-15mV), which is not easily intercepted and engulfed by the liver-based reticuloendothelial system, and the lesion-external organs represented by the liver are less retained. The molecular contrast agent of the drug complex is distributed with the drug, and the aggregation imaging signal in the liver is weak. After the drug easily enters the placental blood vessels, it passes through the gap between the new capillary endothelial cells, reaches and targets the placental sinusoids (villous gaps), and the drug concentration in the placenta is relatively high. The molecular contrast agent of the drug complex is distributed with the drug, and an obvious aggregation imaging signal is produced in the placenta.

[0093] In addition, after the drugs in Examples 1-3 enter the lesions, the GSH shell reacts with the lesion ROS, producing a microenvironment antioxidant therapeutic effect, and significant shell dissociation and release of the strongly positively charged core "PLys-S-PPhe" occur. After the core is released and the overall surface positive charge of the drug increases, it is easy to promote endocytosis of diseased cells in the placenta, produce a cell-targeted delivery effect of the drug, and produce a lesion-targeted retention effect of the positively charged core. After endocytosis, the "thioether bond" of the drug core dissociates in the cell in a targeted manner, promoting core disintegration, drug release, and therapeutic effects. Therefore, the blood pressure of this group of animals has been significantly restored, and the fetal weight and number of litters per litter have been significantly restored.

[0094] The shell of comparative example 1 is a PEG shell connected by chemical bonds, and the potential is relatively low, and it is not easy to be engulfed by the reticuloendothelial system represented by the liver. And the drug shell does not have GSH that can react with ROS in the lesion. After the drug enters the lesion, the shell cannot react with the lesion ROS, and does not produce microenvironment antioxidant therapeutic effects, and no obvious shell dissociation and strong positive core release occur. There is no lesion-specific PLys-S-PPhe carrier core release effect, and the placenta is less aggregated compared to the embodiment. The surface potential of the drug in the lesion is relatively low, and the cell endocytosis efficiency is relatively low compared to the embodiment, and the therapeutic effect is relatively weak. Therefore, compared to the embodiment, the blood pressure recovery of this group of animals is relatively poor, and the fetal weight and the number of litters per litter are relatively poor.

[0095] The shell of comparative example 2 is an adsorbed GSH shell, which can shield the strong positive core, and the drug as a whole is a weaker positive potential, which is not easily engulfed by the reticuloendothelial system represented by the liver. After entering the lesion, the GSH shell reacts with the lesion ROS, produces a microenvironment antioxidant therapeutic effect, and obvious shell dissociation and strong positive core "PLys-PPhe" release occur. After the core is released and the overall surface positive charge of the drug increases, it is easy to promote the endocytosis of the diseased cells in the placenta, produce the cell-targeted delivery effect of the drug, and also produce the lesion-targeted retention effect of the positive core. However, compared with the embodiment, the drug core does not have a "thioether bond" in the cell after endocytosis, and the core disintegration and drug release are more difficult. Compared with the embodiment, the therapeutic effect is weaker. Therefore, compared with the embodiment, the blood pressure recovery of this group of animals is not obvious, and the fetal weight and the number of litters per litter are poorly recovered.

[0096] In Comparative Example 3, due to the lower potential of the inner core, the overall binding of the therapeutic plasmid is less, and the therapeutic effect is weaker than that of the embodiment. Therefore, compared with the embodiment, the blood pressure recovery, fetal weight and litter size of the animals in this group are poorer.

[0097] In Comparative Example 4, since the potential of the nanocarrier as a whole and the inner core is significantly higher than that of the embodiment, after microenvironment retention and endocytosis, the reticuloendothelium retains too much drug, resulting in less drug reaching the placenta, and the imaging signal in the placenta is reduced compared with the embodiment. And the cytotoxicity is large, which affects the therapeutic effect, and the therapeutic effect is poor. Therefore, compared with the embodiment, the blood pressure recovery, fetal weight and number of litters per litter of this group of animals are poor.

[0098] In comparative example 5, the surface overall composite GSH is less, the overall potential of the nanocarrier is higher, and after microenvironment retention and endocytosis, the reticuloendothelial retention of drugs is too much, resulting in less drugs reaching the placenta, and the imaging signal in the placenta is reduced compared with the embodiment. And the cytotoxicity is greater, affecting the therapeutic effect, and the therapeutic effect is poor. Therefore, compared with the embodiment, the blood pressure recovery, fetal weight and number of litters per litter of this group of animals are poor.

[0099] 3. Toxicity evaluation of drugs in animal models

[0100] 72 hours after the injection of the drug, the mice in the normal control group were blooded from the tail vein to detect liver function indicators alanine transaminase (ALT), total bilirubin (TBil) and renal function indicators blood urea nitrogen (BUN) and serum creatinine (sCr). The detection instrument was Hitachi 7600 automatic biochemical analyzer, and the test results are shown in Table 5.

[0101] Table 5 Toxicity evaluation results

[0102]

[0103]

[0104] As shown in Table 5, the carrier system prepared by the present invention is not easily intercepted and engulfed by the reticuloendothelial system mainly composed of the liver, and is less retained in the organs outside the lesion represented by the liver, and has low liver toxicity. These drugs achieve efficient distribution similar to lesion targeting in the placenta, the blood drug concentration is reduced, the kidneys do not produce obvious toxic reactions, and the renal function does not change significantly.

Claims

1. A carrier system based on glutathione to achieve targeted drug delivery in response to microenvironmental reactive oxygen species. It is characterized in that The core of the carrier system is a micelle formed by self-assembly of a diblock copolymer PLys-S-PPhe, and glutathione and therapeutic genes are compounded on the surface of the micelle through electrostatic adsorption.

2. The carrier system for achieving targeted drug delivery based on glutathione response to microenvironment reactive oxygen species according to claim 1, It is characterized in that The structural formula of the diblock copolymer PLys-S-PPhe is: Among them, x=40-60, y=20-30.

3. The carrier system for targeted drug delivery based on glutathione response to microenvironment reactive oxygen species according to claim 1, It is characterized in that The therapeutic gene is FSTL3.

4. The carrier system for achieving targeted drug delivery based on glutathione response to microenvironment reactive oxygen species according to claim 1, It is characterized in that The surface potential of the diblock copolymer PLys-S-PPhe is 20-42 mV.

5. The carrier system for achieving targeted drug delivery based on glutathione response to microenvironment reactive oxygen species according to claim 1, It is characterized in that The surface potential of the carrier system is 3-15 mV.

6. A method for preparing a carrier system for targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen species according to any one of claims 1 to 5, It is characterized in that The steps include: (1) Using n-butylamine as initiator, the ring-opening polymerization of N6-benzyloxycarbonyl-L-lysine anhydride Lys-NCA was initiated to obtain to poly(N-benzyloxycarbonyllysine) PZLL; (2) PZLL and acrylic acid were connected by amidation reaction to introduce double bonds and synthesize double-bond terminated poly(N-benzyloxycarbonyl) Lys)-vinyl PZLL-vinly; (3) PZLL-vinly was treated with azobisisobutyronitrile to add double bonds with the thiol group of cysteamine to synthesize the amino-terminated polymer PZLL-S-NH2 connected with a thioether bond; (4) Using the terminal amino group of PZLL-S-NH2 as an initiator, the ring-opening polymerization of L-phenylalanine-N-carboxyl ring anhydride Phe-NCA was initiated to obtain PZLL-S-PPhe; (5) After the benzyl ester group of the PZLL-S-PPhe side chain is removed by deprotection, the PZLL-S-PPhe self-assembles in an aqueous solution to form poly-lysine-thioether bond-poly-phenylalanine PLys-S-PPhe nanoparticles; (6) PLys-S-PPhe nanoparticles were prepared by electrostatic adsorption with glutathione and therapeutic genes to form a carrier system based on glutathione response to microenvironmental reactive oxygen species for targeted drug delivery.

7. The method for preparing a carrier system for targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen species according to claim 6, It is characterized in that In step (2), the molar ratio of PZLL to acrylic acid is 1:1 to 1:

2.

8. The method for preparing a carrier system for achieving targeted drug delivery based on glutathione response to microenvironment active oxygen according to claim 6, It is characterized in that In step (3), the molar ratio of PZLL-vinly to cysteamine is 1:1 to 1:

2.

9. Use of the carrier system for achieving targeted drug delivery based on glutathione in response to microenvironmental reactive oxygen species according to any one of claims 1 to 5 in the preparation of drugs for treating diseases related to intraplacental oxidative stress.

10. The use according to claim 9, It is characterized in that The intraplacental oxidative stress-related disease is preeclampsia.

Citation Information

Patent Citations

  • Environment-sensitive tumor-targeting polymer micelle and preparation method thereof

    CN104274834A

  • Glutathione response type target polymer micelle and preparation method and application thereof

    CN108727599A

  • Polymer carrier with pH and redox dual response, drug-loaded micelle, preparation method and application

    CN113549184A

  • Glutathione based delivery system

    US20070141133A1

  • Endosomal cleavable hydrophilic-masked cationic charge delivery vehicles

    WO2023168338A2

Cited By

  • Carrier system for achieving targeted drug delivery on basis of glutathione in response to microenvironmental reactive oxygen species, preparation method therefor, and use thereof

    WO2026037001A1